loader
Please Wait
Applying Filters...

Annual Sales of Montelukast reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Menu
$ API Ref.Price (USD/KG) : 1,134Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 10Singulair

PharmaCompass

01

Brand Name : Singulair

Montelukast Sodium

arrow
Luxepack
Not Confirmed

Brand Name : Singulair

arrow
Luxepack
Not Confirmed

Montelukast Sodium

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2020 Revenue in Millions : 462

2019 Revenue in Millions : 698

Growth (%) : -34

blank

02

Brand Name : Singulair

Montelukast Sodium

arrow
Luxepack
Not Confirmed

Brand Name : Singulair

arrow
Luxepack
Not Confirmed

Montelukast Sodium

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2021 Revenue in Millions : 413

2020 Revenue in Millions : 462

Growth (%) : -11

blank

03

Brand Name : Singulair

Montelukast Sodium

arrow
Luxepack
Not Confirmed

Brand Name : Singulair

arrow
Luxepack
Not Confirmed

Montelukast Sodium

Main Therapeutic Indication : Respiratory Diseases

Currency : USD

2022 Revenue in Millions : 411

2021 Revenue in Millions : 413

Growth (%) : 0

blank

04

Brand Name : Singulair

Montelukast Sodium

arrow
Luxepack
Not Confirmed

Brand Name : Singulair

arrow
Luxepack
Not Confirmed

Montelukast Sodium

Main Therapeutic Indication : Respiratory Diseases

Currency : USD

2023 Revenue in Millions : 404

2022 Revenue in Millions : 411

Growth (%) : -2

blank

05

Brand Name : Singulair

Montelukast Sodium

arrow
Luxepack
Not Confirmed

Brand Name : Singulair

arrow
Luxepack
Not Confirmed

Montelukast Sodium

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2015 Revenue in Millions : 1,092

2014 Revenue in Millions : 931

Growth (%) : -15%

blank

06

Brand Name : Singulair

Montelukast Sodium

arrow
Luxepack
Not Confirmed

Brand Name : Singulair

arrow
Luxepack
Not Confirmed

Montelukast Sodium

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2014 Revenue in Millions : -8.70%

2013 Revenue in Millions :

Growth (%) :

blank

07

Brand Name : Singulair

Montelukast Sodium

arrow
Luxepack
Not Confirmed

Brand Name : Singulair

arrow
Luxepack
Not Confirmed

Montelukast Sodium

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2016 Revenue in Millions : 915

2015 Revenue in Millions : 931

Growth (%) : -2

blank

08

Brand Name : Singulair

Montelukast Sodium

arrow
Luxepack
Not Confirmed

Brand Name : Singulair

arrow
Luxepack
Not Confirmed

Montelukast Sodium

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2017 Revenue in Millions : 732

2016 Revenue in Millions : 915

Growth (%) : -20

blank

09

Brand Name : Singulair

Montelukast Sodium

arrow
Luxepack
Not Confirmed

Brand Name : Singulair

arrow
Luxepack
Not Confirmed

Montelukast Sodium

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2018 Revenue in Millions : 708

2017 Revenue in Millions : 732

Growth (%) : -3%

blank

10

Brand Name : Singulair

Montelukast Sodium

arrow
Luxepack
Not Confirmed

Brand Name : Singulair

arrow
Luxepack
Not Confirmed

Montelukast Sodium

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2019 Revenue in Millions : 698

2018 Revenue in Millions : 708

Growth (%) : -1

blank